Jazz Pharmaceuticals PLC (JAZZ)

Operating return on assets (Operating ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Operating income (ttm)	US$ in thousands	578,580	192,697	45,068	-27,022	-65,528	247,238	250,844	95,708	170,278	294,312	462,150	729,866	378,073	265,904	202,800	208,957	532,374	656,184	711,858	660,774
Total assets	US$ in thousands	11,393,400	11,204,100	11,260,500	11,047,100	10,835,300	10,384,700	11,200,100	11,768,900	12,298,600	12,478,200	13,213,000	6,756,470	6,535,900	6,291,960	6,066,500	5,215,300	5,538,900	5,527,850	5,488,660	5,280,240
Operating ROA		5.08%	1.72%	0.40%	-0.24%	-0.60%	2.38%	2.24%	0.81%	1.38%	2.36%	3.50%	10.80%	5.78%	4.23%	3.34%	4.01%	9.61%	11.87%	12.97%	12.51%

December 31, 2023 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $578,580K ÷ $11,393,400K
= 5.08%

Jazz Pharmaceuticals plc's operating return on assets (operating ROA) has shown a consistent positive trend over the past eight quarters. The operating ROA has steadily increased from 0.81% in Q1 2022 to 5.24% in Q4 2023. This indicates that the company has been effectively generating operating income relative to its total assets. The improvement in operating ROA suggests that Jazz Pharmaceuticals has been able to efficiently utilize its assets to generate operating profits. This trend is favorable as it indicates the company's operational efficiency and profitability are improving over time. Further analysis should be conducted to understand the factors driving this positive performance and to assess the sustainability of this trend.